Evaluation of H3K27me3 Expression as a Marker of EZH2 Activation in SMARCA4/SMARCA2-Deficient Tumors and Candidate Biomarker for Trials of EZH2 Inhibitors

被引：0
|
作者：
Kezlarian, Brie [1 ]
Montecalvo, Joseph [2 ]
Sauter, Jennifer [1 ]
Travis, William [1 ]
Gounder, Mrinal [1 ]
Rudin, Charles [1 ]
Ladanyi, Marc [1 ]
Namakydoust, Azadeh [3 ]
Rekhtman, Natasha [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Suny Downstate Med Ctr, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Middletown, NJ USA
来源：
MODERN PATHOLOGY | 2019年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1844
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Evaluation of H3K27me3 Expression as a Marker of EZH2 Activation in SMARCA4/SMARCA2-Deficient Tumors and Candidate Biomarker for Trials of EZH2 Inhibitors
    Kezlarian, Brie
    Montecalvo, Joseph
    Sauter, Jennifer
    Travis, William
    Gounder, Mrinal
    Rudin, Charles
    Ladanyi, Marc
    Namakydoust, Azadeh
    Rekhtman, Natasha
    LABORATORY INVESTIGATION, 2019, 99
  • [2] EZH2/H3K27Me3 and phosphorylated EZH2 predict chemotherapy response and prognosis in ovarian cancer
    Sun, Si
    Yang, Qiang
    Cai, E.
    Huang, Bangxing
    Yin, Feiquan
    Wen, Yiping
    Cai, Ling
    Yang, Ping
    PEERJ, 2020, 8
  • [3] Dissecting the Role of EZH2 and H3K27me3 in Endometriosis
    Colon-Caraballo, Mariano
    Soto-Vargas, John
    Urrutia, Raul
    Flores, Idhaliz
    FASEB JOURNAL, 2017, 31
  • [4] Characterization of H3K27me3 and EZH2 Isoforms in Endometriosis.
    Colon-Caraballo, Mariano
    Soto-Vargas, John
    Urrutia, Raul
    Flores, Idhaliz
    REPRODUCTIVE SCIENCES, 2016, 23 : 89A - 90A
  • [5] Expression of EZH2 and H3K27me3 predicts tumor biology of urothelial carcinoma
    Mohamedali, Rasheeda
    Mitra, Suvradeep
    Mandal, Swarnendu
    Nayak, Prasant
    Adhya, Amit K.
    Purkait, Suvendu
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2023, 66 (03) : 488 - 494
  • [6] Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer
    Leitner, Katharina
    Tsibulak, Irina
    Wieser, Verena
    Knoll, Katharina
    Reimer, Daniel
    Marth, Christian
    Fiegl, Heidi
    Zeimet, Alain G.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [7] Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer
    Katharina Leitner
    Irina Tsibulak
    Verena Wieser
    Katharina Knoll
    Daniel Reimer
    Christian Marth
    Heidi Fiegl
    Alain G. Zeimet
    Scientific Reports, 10
  • [8] EZH2 -mediated H3K27me3 is a predictive biomarker and therapeutic target in uveal melanoma
    Hou, Chen
    Xiao, Lirong
    Ren, Xiang
    Cheng, Lin
    Guo, Bo
    Zhang, Meixia
    Yan, Naihong
    FRONTIERS IN GENETICS, 2022, 13
  • [9] DZNep attenuates liver fibrosis by blocking EZH2 and H3K27me3
    Zeybel, Mujdat
    Walsh, Meagan J.
    Chu, David C.
    Tsukamoto, Hidekazu
    Mann, Derek A.
    Mann, Jelena
    HEPATOLOGY, 2012, 56 : 772A - 772A
  • [10] Selective killing of SMARCA2-and SMARCA4-deficient tumors by inhibition of EZH2: In vitro and in vivo preclinical models
    Chan-Penebre, Elayne
    Armstrong, Kelli
    Drew, Allison
    Grassian, Alexandra R.
    Feldman, Igor
    Roche, Maria
    Ho, Peter
    Brach, Dorothy
    Raimondi, Alejandra
    Copeland, Robert A.
    Chesworth, Richard
    Smith, Jesse J.
    Ribich, Scott A.
    CANCER RESEARCH, 2017, 77
12345